Artivion, Inc.'s decision to pull the PROACT Xa trial resulted in heavy downside for the share price. Investors have sold positions rapidly such that the stock trades at multi-year lows.
ATLANTA , Sept. 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at the upcoming Deu
ATLANTA , Sept. 6, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming
ATLANTA , Aug. 24, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present virtually at the upc
Artivion, Inc. (NYSE:AORT ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group James Mackin - Chairman, President & CEO David Lee - EVP, C
Artivion (AORT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Artivion, Inc. (NYSE:AORT ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Brian Johnston - Investor Relations Pat Mackin - Chief Executive Officer Ashley Lee - Chief Fin
Artivion, Inc. (AORT) CEO J. Patrick Mackin on Q4 2021 Results - Earnings Call Transcript
Artivion (AORT) delivered earnings and revenue surprises of 100% and 1.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE